Anne-Emmanuelle LUGRIN,Claude GRISCELLI,Mehdi EL GLAOUI,Guillaume EL GLAOUI,Jean HOFFELT
申请号：
MX2010008071
公开号：
MX344778B
申请日:
2009.01.26
申请国别(地区):
MX
年份:
2017
代理人:
摘要：
Oral pharmaceutical dosage form containing at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another, at least one of the medicaments being selected from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, clopidogrel.La presente invención se refiere a el uso de una inmunoadhesina ALJK-1 en la manufactura de un medicamento para inhibir la linfoangiogéneis asociada con una condición patológica en un sujeto, en donde la condición patológica es seleccionada del grupo que consiste en: cáncer, tumor o metástasis cancerosa, trastorno proliferativo celular, degeneración macular, enfermedad inflamatoria, artritis reumatoide, retinopatía diabética y psoriasis, y en donde la inmunoahesina ALK-1 comprende residuos aminoácidos 22-352 de SEQ ID NO: 2, residuos 22-349 de SEQ ID NO: 4, residuos 22-347 de SEQ ID NO: 6, residuos 22-350 de SEQ ID NO: 8 o residuos 22-350 de SEQ ID NO: 10.
